ReviewLung2026

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Mario Cazzola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.